Fig. 5From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanomaB cell subsets paired with chemokine levels correlate with OS. Kaplan-Meier OS curves comparing patients with high Bm2 population and low levels of listed chemokine (<67 pg/ml for CCL3, or <600 pg/ml for CCL4 or <76 pg/ml for CXCL8) versus all other patients (others). P values were calculated using the log-rank test and are shown on each graphBack to article page